Last edition
News about "Psoriasis Area"
Johnson & Johnson Reports Positive Phase 3 Results for Icotyde in Psoriatic Arthritis
Johnson & Johnson reported positive Phase 3 results for Icotyde, an oral IL-23 receptor-targeting peptide being investigated for the treatment of psoriatic arthritis.
Psoriasis Area | 10/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members